Trump Budget Backs Medical Cannabis Protection, Blocks DC Retail Sales
President's FY2027 budget maintains federal protections for state medical programs while continuing restrictions on Washington DC recreational market.
President Trump's fiscal 2027 budget proposal delivers a mixed message for cannabis markets, backing continued federal protections for state medical marijuana programs while maintaining restrictions that prevent Washington DC from establishing recreational sales. The dual approach reflects the administration's nuanced stance on cannabis policy, supporting medical access while drawing lines on broader legalization efforts.
The budget request marks the first time Trump has explicitly endorsed the Rohrabacher-Farr amendment protections in a formal budget proposal, signaling potential stability for the $7.3 billion medical cannabis market. These protections prevent the Department of Justice from using federal funds to prosecute state-compliant medical marijuana operations, providing crucial regulatory certainty for operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) that derive substantial revenue from medical programs across multiple states.
The continued block on DC recreational sales represents a strategic political calculation that could influence broader federal cannabis policy. Washington DC's restricted market serves as a testing ground for federal attitudes toward adult-use legalization, and maintaining these limitations suggests the administration remains cautious about full recreational endorsement despite growing state-level momentum.
For cannabis operators, the medical program protections provide operational stability in key markets like Florida, Pennsylvania, and Ohio, where medical sales generate hundreds of millions in annual revenue. However, the DC restrictions underscore ongoing federal hesitancy that could impact broader rescheduling efforts and interstate commerce development.
The budget proposal arrives as Congress debates broader cannabis reform measures and the industry awaits final DEA action on marijuana rescheduling. While medical protections offer near-term stability, the selective approach highlights the complex regulatory environment that continues to constrain institutional investment and banking access across the cannabis sector.